Exelixis Inc. is heartened by broader inclusion in National Comprehensive Cancer Network (NCCN) clinical practice guidelines for Cabometyx (cabozantinib) across risk groups in first-line kidney cancer, though the tyrosine kinase inhibitor doesn't have as high of a rating as Bristol-Myers Squibb Co.'s immunotherapy combination of Yervoy and Opdivo.
Cabozantinib is an oral drug that works on a number of targets, including VEGFR2, MET and RET. The drug was approved by the US FDA in 2013 for treating the very rare medullary thyroid cancer and labeling was expanded in April 2016 to second-line renal cell carcinoma (RCC) in December 2017 to all lines of advanced RCC
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?